Inhibrx Historical Income Statement

INBX Stock

USD 15.01 0.07 0.47%

Historical analysis of Inhibrx income statement accounts such as Tax Provision of 2.6 K or Depreciation And Amortization of 1.1 M can show how well Inhibrx performed in making a profits. Evaluating Inhibrx income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Inhibrx's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Inhibrx latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Inhibrx is a good buy for the upcoming year.

Net Income Gross Profit

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inhibrx. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy Inhibrx Stock please use our How to Invest in Inhibrx guide.

About Inhibrx Income Statement Analysis

Inhibrx Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Inhibrx shareholders. The income statement also shows Inhibrx investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Inhibrx Income Statement Chart

At this time, Inhibrx's Interest Expense is fairly stable compared to the past year. Selling General Administrative is likely to rise to about 30.9 M in 2024, despite the fact that Net Loss is likely to grow to (124.2 M).

Selling General Administrative Total Revenue Other Operating Expenses

Total Revenue

Total revenue comprises all receipts Inhibrx generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Inhibrx. It is also known as Inhibrx overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from Inhibrx's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Inhibrx current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inhibrx. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy Inhibrx Stock please use our How to Invest in Inhibrx guide.At this time, Inhibrx's Interest Expense is fairly stable compared to the past year. Selling General Administrative is likely to rise to about 30.9 M in 2024, despite the fact that Net Loss is likely to grow to (124.2 M).

	2021	2022	2023	2024 (projected)
Total Operating Expenses	83.7M	131.3M	219.8M	230.8M
Cost Of Revenue	2.7M	2.8M	1.2M	1.1M

Total Operating Expenses Cost Of Revenue

Inhibrx income statement Correlations

	Tax Provision	Net Interest Income	Depreciation And Amortization	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Reconciled Depreciation	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Non Operating Income Net Other	Interest Income	Selling And Marketing Expenses
Tax Provision		0.44	-0.23	-0.41	0.39	-0.83	-0.47	0.47	0.48	0.48	-0.47	0.48	0.4	-0.47	-0.2	0.47	0.37	0.46	1.0	0.55	-0.34	0.34
Net Interest Income	0.44		-0.79	-0.95	0.7	-0.64	-0.96	0.97	0.98	0.97	-0.96	0.97	0.38	-0.96	-0.79	0.97	0.99	0.97	0.44	0.81	-0.77	0.74
Depreciation And Amortization	-0.23	-0.79		0.8	-0.43	0.54	0.75	-0.76	-0.82	-0.78	0.75	-0.77	-0.2	0.76	1.0	-0.77	-0.84	-0.77	-0.23	-0.78	0.46	-0.41
Selling General Administrative	-0.41	-0.95	0.8		-0.82	0.55	0.99	-0.99	-0.99	-0.99	0.98	-0.99	-0.57	0.99	0.79	-0.99	-0.97	-0.99	-0.41	-0.9	0.81	-0.82
Total Revenue	0.39	0.7	-0.43	-0.82		-0.28	-0.77	0.79	0.77	0.78	-0.76	0.79	0.87	-0.77	-0.42	0.79	0.72	0.78	0.39	0.81	-0.69	0.68
Gross Profit	-0.83	-0.64	0.54	0.55	-0.28		0.6	-0.6	-0.64	-0.61	0.6	-0.61	-0.24	0.6	0.52	-0.6	-0.59	-0.6	-0.83	-0.67	0.36	-0.35
Other Operating Expenses	-0.47	-0.96	0.75	0.99	-0.77	0.6		-1.0	-0.98	-1.0	1.0	-1.0	-0.51	1.0	0.75	-1.0	-0.97	-1.0	-0.47	-0.86	0.86	-0.86
Operating Income	0.47	0.97	-0.76	-0.99	0.79	-0.6	-1.0		0.99	1.0	-1.0	1.0	0.53	-1.0	-0.75	1.0	0.97	1.0	0.47	0.87	-0.87	0.83
Net Income From Continuing Ops	0.48	0.98	-0.82	-0.99	0.77	-0.64	-0.98	0.99		0.99	-0.98	0.99	0.5	-0.98	-0.82	0.99	0.99	0.99	0.48	0.9	-0.79	0.76
Ebit	0.48	0.97	-0.78	-0.99	0.78	-0.61	-1.0	1.0	0.99		-1.0	1.0	0.52	-1.0	-0.77	1.0	0.98	1.0	0.48	0.88	-0.85	0.82
Research Development	-0.47	-0.96	0.75	0.98	-0.76	0.6	1.0	-1.0	-0.98	-1.0		-1.0	-0.49	1.0	0.74	-1.0	-0.97	-1.0	-0.47	-0.85	0.86	-0.87
Ebitda	0.48	0.97	-0.77	-0.99	0.79	-0.61	-1.0	1.0	0.99	1.0	-1.0		0.52	-1.0	-0.76	1.0	0.98	1.0	0.48	0.88	-0.85	0.82
Cost Of Revenue	0.4	0.38	-0.2	-0.57	0.87	-0.24	-0.51	0.53	0.5	0.52	-0.49	0.52		-0.51	-0.19	0.52	0.41	0.51	0.4	0.74	-0.48	0.47
Total Operating Expenses	-0.47	-0.96	0.76	0.99	-0.77	0.6	1.0	-1.0	-0.98	-1.0	1.0	-1.0	-0.51		0.75	-1.0	-0.97	-1.0	-0.47	-0.86	0.86	-0.86
Reconciled Depreciation	-0.2	-0.79	1.0	0.79	-0.42	0.52	0.75	-0.75	-0.82	-0.77	0.74	-0.76	-0.19	0.75		-0.76	-0.83	-0.77	-0.2	-0.77	0.46	-0.41
Income Before Tax	0.47	0.97	-0.77	-0.99	0.79	-0.6	-1.0	1.0	0.99	1.0	-1.0	1.0	0.52	-1.0	-0.76		0.98	1.0	0.47	0.87	-0.86	0.83
Total Other Income Expense Net	0.37	0.99	-0.84	-0.97	0.72	-0.59	-0.97	0.97	0.99	0.98	-0.97	0.98	0.41	-0.97	-0.83	0.98		0.98	0.37	0.84	-0.77	0.74
Net Income	0.46	0.97	-0.77	-0.99	0.78	-0.6	-1.0	1.0	0.99	1.0	-1.0	1.0	0.51	-1.0	-0.77	1.0	0.98		0.46	0.87	-0.86	0.82
Income Tax Expense	1.0	0.44	-0.23	-0.41	0.39	-0.83	-0.47	0.47	0.48	0.48	-0.47	0.48	0.4	-0.47	-0.2	0.47	0.37	0.46		0.55	-0.34	0.34
Non Operating Income Net Other	0.55	0.81	-0.78	-0.9	0.81	-0.67	-0.86	0.87	0.9	0.88	-0.85	0.88	0.74	-0.86	-0.77	0.87	0.84	0.87	0.55		-0.63	0.61
Interest Income	-0.34	-0.77	0.46	0.81	-0.69	0.36	0.86	-0.87	-0.79	-0.85	0.86	-0.85	-0.48	0.86	0.46	-0.86	-0.77	-0.86	-0.34	-0.63		-0.81
Selling And Marketing Expenses	0.34	0.74	-0.41	-0.82	0.68	-0.35	-0.86	0.83	0.76	0.82	-0.87	0.82	0.47	-0.86	-0.41	0.83	0.74	0.82	0.34	0.61	-0.81

Click cells to compare fundamentals

Inhibrx Account Relationship Matchups

Inhibrx income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Interest Expense	5.7M	10.8M	5.2M	16.1M	31.8M	33.4M
Net Income Applicable To Common Shares	(51.4M)	(76.1M)	(81.8M)	(145.2M)	(130.7M)	(124.2M)
Tax Provision	96K	898K	3K	2K	2.7K	2.6K
Net Interest Income	(5.7M)	(10.8M)	(5.2M)	(16.1M)	(19.9M)	(18.9M)
Depreciation And Amortization	1.1M	1.0M	1.2M	1.2M	1.2M	1.1M
Selling General Administrative	9.0M	6.8M	12.4M	21.1M	29.4M	30.9M
Total Revenue	9.1M	12.8M	7.1M	2.2M	1.8M	1.7M
Gross Profit	(38.8M)	12.8M	7.1M	2.2M	609K	639.5K
Other Operating Expenses	52.8M	80.3M	83.7M	131.3M	221.0M	232.1M
Operating Income	(43.7M)	(67.4M)	(76.6M)	(129.1M)	(219.2M)	(208.3M)
Net Income From Continuing Ops	(51.4M)	(76.1M)	(81.8M)	(145.2M)	(188.7M)	(179.2M)
Ebit	(43.7M)	(67.4M)	(76.6M)	(129.1M)	(207.9M)	(197.5M)
Research Development	47.9M	73.5M	71.4M	110.2M	191.6M	201.2M
Ebitda	(42.6M)	(66.4M)	(75.4M)	(127.9M)	(206.7M)	(196.4M)
Cost Of Revenue	47.9M	73.5M	2.7M	2.8M	1.2M	1.1M
Total Operating Expenses	52.8M	80.3M	83.7M	131.3M	219.8M	230.8M
Reconciled Depreciation	676K	1.2M	1.0M	1.2M	1.2M	1.1M
Income Before Tax	(50.5M)	(75.6M)	(81.8M)	(145.2M)	(239.7M)	(227.7M)
Total Other Income Expense Net	(6.8M)	(8.2M)	(5.2M)	(16.1M)	(20.5M)	(19.5M)
Net Income	(51.4M)	(75.6M)	(81.8M)	(145.2M)	(241.4M)	(229.3M)
Income Tax Expense	96K	898K	3K	2K	2.7K	2.6K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Inhibrx Stock Analysis

When running Inhibrx's price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Inhibrx Historical Income Statement

About Inhibrx Income Statement Analysis

Inhibrx Income Statement Chart

Total Revenue

Other Operating Expenses

Inhibrx income statement Correlations

Inhibrx Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Inhibrx income statement Accounts

Also Currently Popular

Additional Tools for Inhibrx Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Interest Expense	Net Income Applicable To Common Shares
Minority Interest	Tax Provision
Net Interest Income	Depreciation And Amortization
Selling General Administrative	Total Revenue
Gross Profit	Other Operating Expenses
Operating Income	Net Income From Continuing Ops
Ebit	Research Development
Ebitda	Cost Of Revenue
Total Operating Expenses	Reconciled Depreciation
Income Before Tax	Total Other Income Expense Net
Net Income	Income Tax Expense
Non Operating Income Net Other	Interest Income
Selling And Marketing Expenses

Income Tax Expense	+ 1.0	Tax Provision
Reconciled Depreciation	+ 1.0	Depreciation And Amortization
Research Development	+ 1.0	Other Operating Expenses
Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebit	+ 1.0	Operating Income
Ebitda	+ 1.0	Operating Income

Net Income	- 1.0	Total Operating Expenses
Income Before Tax	- 1.0	Total Operating Expenses
Total Operating Expenses	- 1.0	Ebitda
Net Income	- 1.0	Research Development
Income Before Tax	- 1.0	Research Development
Ebitda	- 1.0	Research Development